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Background: Copy neutral loss of heterozygosity (CN-LOH) refers to a special case of LOH occurring without any
resulting loss in copy number. These alterations is sometimes seen in tumors as a way to inactivate a tumor
suppressor gene and have been found to be important in several types of cancer.
Results: We have used high density single nucleotide polymorphism arrays in order to investigate the frequency
and distribution of CN-LOH and other allelic imbalances in neuroblastoma (NB) tumors and cell lines. Our results
show that the frequency of these near-CN-LOH events is significantly higher in the cell lines compared to the
primary tumors and that the types of CN-LOH differ between the groups. We also show that the low-risk
neuroblastomas that are generally considered to have a “triploid karyotype” often present with a complex
numerical karyotype (no segmental changes) with 2-5 copies of each chromosome. Furthermore a comparison has
been made between the three related cell lines SK-N-SH, SH-EP and SH-SY5Y with respect to overall genetic
aberrations, and several aberrations unique to each of the cell lines has been found.
Conclusions: We have shown that the NB tumors analyzed contain several interesting allelic imbalances that
would either go unnoticed or be misinterpreted using other genome-wide techniques. These findings indicate that
the genetics underlying NB might be even more complex than previously known and that SNP arrays are
important analysis tools. We have also showed that these near-CN-LOH events are more frequently seen in NB cell
lines compared to NB tumors and that a set of highly related cell lines have continued to evolve secondary to the
subcloning event. Taken together our analysis highlights that cell lines in many cases differ substantially from the
primary tumors they are thought to represent, and that caution should be taken when drawing conclusions from
cell line-based studies.
Background
Neuroblastoma (NB) is the most common extracranial
solid tumor of childhood, a malignancy believed to
arise from primitive cells of the sympathetic nervous
system. This disease is characterized by a high degree
of heterogeneity, ranging from spontaneously regres-
sing growth to highly malignant tumors [1]. The most
common genetic abnormalities found in aggressive NB
tumors are partial deletion of chromosome arms 1 p
and/or 11 q, gain of genetic material for chromosome
arm 17 q and amplification of the proto-oncogene
MYCN [1-5]. Several different types of array based
methods have been used over the past few years for
assessing copy number changes on a genome wide
scale in NB tumors [4-14]. The resulting pattern of
genetic alterations is used today to classify the tumors
into prognostic subgroups, indicative for the treatment
of the patients. Generally, tumors with a near-triploid
appearance, containing only numerical aberrations (i.e
gains and losses of whole chromosomes), have a very
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tion and tumors with 11 q deletion constitute two
groups with unfavorable prognosis and poor survival.
Both these latter groups typically also present with 17
q gain [4,5]. Furthermore, we have found that tumors
presenting with 17 q gain, but without MYCN amplifi-
cation or 11 q deletion, form a group with intermedi-
ate prognosis, and that tumors presenting with other
segmental aberrations (i.e without MYCN amplifica-
tion, 11 q deletion or 17 q gain) have a favorable prog-
nosis [4]. In this study we have used high density
single nucleotide polymorphism (SNP)-arrays from
Affymetrix. These arrays have the advantage over
BAC-based array-CGH that hybridization intensities
are recorded also for each allele of an SNP, which
gives simultaneous information on both LOH and copy
number status. To ensure proper detection of LOH
regions in the case of stromal cell contamination or
clonal differences within the tumor, we have used the
AsCNAR algorithm available in CNAG 3.0 [15]. When
calculating the allele specific intensities, this algorithm
takes advantage of the false heterozygous calls that
might appear as a result of contaminating normal cells
[16]. This makes it a robust method for visualizing
LOH and other allelic imbalances even in complex
tumor materials.
One type of alteration that typically goes unnoticed
using conventional array-CGH platforms is copy neutral
loss of heterozygosity (CN-LOH), a special case of LOH
occurring without any resulting loss in copy number.
This phenomenon might; (i) be a case of identical by
descent (IBD) i.e. two identical copies of a particular
region are inherited independently of each other due to
parents that are closely related to each other, (ii) be an
effect of uniparental disomy (UPD), i.e. both copies are
derived from the same parent, as in the Prader Willi
and Angelmans syndromes or (iii) be a tumor acquired
event where a homozygous situation is achieved by los-
ing one copy and then compensating for this with dupli-
cation of the other allele. This is most often denoted in
the literature as CN-LOH, or sometimes also as
acquired UPD. In this article we refer to CN-LOH as
the tumor acquired form and specifically use IBD or
UPD when appropriate.
CN-LOH is sometimes seen in tumors as a way to
inactivate tumor suppressor genes, and has been
reported in many different types of cancer [17]. Here we
present data regarding the frequency and appearance of
copy neutral events and other allelic imbalances in a
panel of 134 primary NB tumors and 10 NB cell lines.
We also present full genomic profiles for 10 NB cell
lines and discuss evolutionary differences between
related cell lines.
Methods
Samples and DNA preparation
134 primary NB tumors from Sweden, 66 of stage L, 51
of stage M, 4 of stage MS and 13 of unknown stage,
were included in this study. The stages are according to
the recently introduced INRG classification [18]. Ten
NB cell lines were also analyzed; IMR32, Kelly, NB69,
SH-SY5Y, SK-N-AS, SK-N-BE(2), SK-N-DZ, SK-N-FI,
SK-N-SH (ECACC, HPA Culture Collections, Salisbury,
UK) and SH-EP (ATCC, Manassas, VA), as well as con-
stitutional DNA from 30 healthy blood donors. The pri-
mary tumors were histologically assessed for tumor cell
content using adjacent tumor tissue to that used for
DNA extraction, and total genomic DNA was then iso-
lated using DNeasy blood and tissue kit (Qiagen, Hilden,
Germany) according to the manufacturer’si n s t r u c t i o n s .
Informed consent was retrieved from the parents of the
patients. Ethical permission was granted by the local
ethics committee (Karolinska Institutet and Karolinska
University Hospital, registration number 03-736 and
2009/1369).
Cell line validation
STR typing of the cell lines was performed using the
AmpFLSTR
® Identifiler
® kit (Applied biosystems; i.e. the
so called CODIS kit) according to the user manual (PN
4323291) and the validation report (Applied Biosystems
3730 DNA Analyzer Human Identification Validation
Report, October 2007) with the following changes: PCR
amplification was run in 10 μl reactions in a 384well for-
mat, using 2ng DNA as template and 25 cycles of anneal-
ing/elongation. Heat sealing film was used to seal the
plates and the amplification was run in a GeneAmp
®
PCR System 9700 without 9600 emulation, followed by
fragment analysis using a 3730 DNA analyzer with POP7
polymer and 10s injection time. GeneScan500 LIZ
® was
used as size standard and AmpFLSTR
® Identifiler
® Alle-
lic Ladder as well as a control DNA (Q9947A) was always
r u ni np a r a l l e lt ot h es a m p les. GeneMapper v3.6 was
used for analysis with peak window size set to 11 points.
STR genotype profiles for each cell line were compared
with that of the Children’s Oncology Group (COG) Cell
Culture and Xenograft Repository web page (http://strdb.
cogcell.com/).
High resolution SNP array analysis
The tumors where analyzed for copy number changes
and LOH using either Genechip
® Human Mapping 50K
XbaI (22 samples) or Genechip
® Human Mapping 250K
NspI (112 samples; Affymetrix Inc., Santa Clara, CA). A
number of these cases have been presented before [3,4],
albeit analyzed for other features. The experimental pro-
cedure has been previously described [3].
Kryh et al. BMC Genomics 2011, 12:443
http://www.biomedcentral.com/1471-2164/12/443
Page 2 of 11Data analysis and software
GeneChip
® operating software (GCOS) and Gene-
Chip
® Genotyping Analysis Software (GTYPE;Affyme-
trix) were used for primary data analysis,
normalization against internal control features on the
chip, genotype calling and quality control. Subsequent
analysis was then performed using Copy Number Ana-
lyzer for GeneChip (CNAG 3.0;Genome Laboratory,
Tokyo University) [19] featuring the algorithm for
Allele-specific Copy-Number analysis using Anon-
ymous References (AsCNAR) [15,16]. In CNAG, the
tumor samples were compared in silico to the 6 best
matched control samples (lowest standard deviation)
available among a set of non-matched healthy indivi-
duals. This set contained both HapMap samples avail-
able from Affymetrix as well as our own set of healthy
control samples.
Fluorescent In Situ Hybridization (FISH) analysis
FISH analysis for chromosome 1 (1pter and 1cen), 2
(MYCN) and sometimes 17 and/or 18, has been per-
formed on most of the tumors in the NB material for
diagnostic purposes. The experimental procedure has
been described elsewhere [20]. The available FISH-data
was used as a comparison for the copy number estima-
tions from CNAG on a per chromosome basis.
Multiplex ligation-dependent probe amplification (MLPA)
MLPA analysis for copy number changes in the
CDKN2A/2B region at 9p21 was performed using the
Salsa MLPA Kit P024B (MRC-Holland, Amsterdam, the
Netherlands). The analysis was performed according to
the protocol provided by the supplier with some minor
changes [3].
Statistical analysis
Fisher’s exact test was used to compare the proportions
of samples presenting with at least one near-CN-LOH
event while the actual frequency of near-CN-LOH
events was compared using the Mann Whitney U test.
The near-CN-LOHs were also divided into three differ-
ent subcategories; interstitial (small, segmental events
within the chromosome), telomeric (segmental events
extending to one end of the chromosome) and whole
chromosome events (including the entire chromosome).
For simplification the × chromosome was excluded, and
the cell-lines SH-EP and SH-SY5Y were also omitted
from the analysis due to their shared ancestry with the
cell line SK-N-SH. Array profiles indicative of a high
content of stroma cell contamination, i.e. cases without
any visible aberrations (flat profile), with MYCN amplifi-
cation only or with CN-LOH only, were also removed
from the analysis.
Results
Copy number estimations in complex tumors
The NB tumors and cell lines were analyzed with
respect to copy number change and LOH using CNAG
3.0. General ploidy information was also derived from
these array data, and in many near triploid cases the
copy number for the individual chromosomes differed
widely. Although this posed some difficulties in asses-
sing the overall ploidy, the allele specific intensities from
the AsCNAR algorithm still made it possible to estimate
the copy number on a per chromosome basis, even for
the more complex triploid or tetraploid tumors (Figure
1). This was achieved by sequentially comparing the
total copy number for each chromosome with the corre-
sponding allele based intensities, thus trying to fit the
most appropriate copy number to each intensity level.
The estimated copy numbers were then compared to
FISH data, whenever available. Although we only had
access to FISH data for a few chromosomes, it corre-
lated well with the copy number estimates from CNAG
and only a few cases needed to be revised due to tetra-
ploid tumors being erroneously classified as diploid
tumors.
What is copy neutral in a near triploid tumor?
When these polyploid tumors were analyzed regarding
CN-LOH it was found that many different types of
LOH exist in these tumors that are not exactly copy
neutral, nor are they representing classical hemizygous
deletions. Due to the AsCNAR algorithm, these regions
of LOH are clearly distinguished from regions with a
maintained heterozygosity, even in complex triploid or
tetraploid tumors (Figure 1). These findings brought up
the question whether CN-LOH is a relevant measure in
these tumors, and led us to broaden the definition of
CN-LOH to include all LOH that are at least partially
compensated by the remaining allele, from now on
referred to as “near CN-LOH”.T h u s ,i nan e a r - t r i p l o i d
tumor, allelic distributions of 2+0 or 3+0 are both con-
sidered as “near CN-LOH”. Additionally, other allelic
imbalances not involving LOH, such as allelic distribu-
tions of 3+1 vs. 2+2 or 4+1 vs. 3+2 were identified in
the tumors, but since most of these cases are imbalances
rather than true loss of heterozygosity, they were not
included in the statistical calculations.
Frequency of near CN-LOH in NB
35% (47/134) of the primary NB tumors presented with at
least one region of near-CN-LOH, compared with 87% (7/
8) of the NB cell lines (p = 0.005). The actual frequency of
near-CN-LOH was also found to be higher in the cell lines
(median: 2 events; mean: 2.4; 25th-75th percentiles: 1-3.5)
as compared to the primary tumors (median = 0 events;
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the near-CN-LOH seen in the primary tumors might be
due to IBD, a comparison was also made between the pri-
mary tumors and the set of healthy controls. The amount
of near-CN-LOH was higher in the primary tumors
(median: 0 events; mean: 0.89; 25th-75th percentiles: 0-1)
as compared to the controls (median: 0 events; mean: 0.10;
25th-75th percentiles: 0-0) (p = 0.005), indicating that the
frequency of CN-LOH in the tumors is not solely
accounted for by IBD events.
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NB02 – 65XX
NB01 - 54XX
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Figure 1 Estimating ploidy number in NB tumors with complex genomic profiles. Allele specific intensities, calculated using the AsCNAR
algorithm, makes it possible to estimate the copy number for each chromosome in complex tumors. Arrows indicate differences seen only on
the allele specific level that would have been overlooked or misjudged using other methods, for example 1+1 vs. 2+0 or 2+1 vs. 3+0. Several
examples of near CN-LOH is also shown; chromosomes 3, 4, 10, 11, 12 and 19 all show an allelic distribution of 2+0 in NB01 which has an
overall ploidy of ~2,3n, and chromosome 3 in NB02 has an allelic distribution of 2+0 in an otherwise near triploid tumor (overall ploidy ~2,8n).
The multi-colored line shows the total copy number for the different chromosomes and the red and green lines show the strongest and
weakest allele intensity respectively. Total copy number is written above each chromosome and allele specific copy numbers are written
underneath the allele intensity plot as: red/green.
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whole chromosome) were also found to differ in abun-
dance between the groups. Among the cell-lines the by
far most frequent forms of CN-LOH were telomeric
(74%), followed by whole chromosome events (21%) and
interstitial events (5%). The healthy controls on the
other hand only had the interstitial form of CN-LOH
(100%), while the primary tumors were somewhere in
between, with mostly interstitial events (50%) followed
by whole chromosome events (35%) and telomeric
events (14%).
Furthermore, a comparison was made between the
amount of near-CN-LOH in the tumors and the out-
come of the patients, defined as either dead of disease
or no evidence of disease, i.e. alive and with an overall
survival of at least 5 years. However the number of
near-CN-LOH events was not found to differ between
the two outcome categories, regardless of the CN-LOH
subtype studied.
Distribution and chromosomal locations of near CN-LOH
in NB
The distribution of near CN-LOH in the tumors seems
to be relatively even across the genome, with all chro-
mosomes affected in at least one tumor sample, except
for chromosome 20 (data not shown). Some of the near-
C N - L O H si nt h ep r i m a r yt u m o r sw e r ef o u n di nt h e
regions of 1 p and 11 q and some cases of gain-LOH
were also found in the region of 17 q (Figure 2). These
three regions are thought to be of clinical interest and
are often affected with loss or gain in aggressive NB
tumors. The cell lines also display a distribution of
near-CN-LOH that is fairly scattered, although the over-
all frequency is increased compared to that in the pri-
mary tumors. Genome-wide array profiles are shown in
Figure 3 for all cell lines examined.
Genetic differences between closely related cell lines
The cell line SK-N-SH has been described as consisting
of two distinct morphological cell types, one neuroblast-
like and one epithelial-like, and sub-clonal cell lines
have therefore been established from SK-N-SH in sev-
eral subsequent steps [21]. We compared the array pro-
files for two of the resulting cell lines; SH-EP (epithelial-
like) and SH-SY5Y (neuroblast-like), to each other and
to the array profile of the parental cell line SK-N-SH in
order to identify possible genetic differences that have
occurred during the sub-cloning (Figure 4).
The three cell lines were found to be strikingly similar
and shared many of the aberrations, for example trisomy
for chromosome 7 and partial CN-LOH at 14 q and 22 q.
One aberration (2 p gain) was also found to be shared
between the parental cell line and one of the daughter
cell lines (SH-SY5Y). However, several unique alterations
were also found for each of the cell lines (Figure 4 and
Additional file 1), for example in the SH-EP cell line a
homozygous deletion was detected at 9p21.3 in the
region containing the genes CDKN2A and CDKN2B.
This deletion, as well as a small gain found in a nearby
region in SH-SY5Y was confirmed using MLPA (Figure
4b). Interestingly, although a gain at 1 q is seen in both
daughter cell lines (SH-SY5Y and SH-EP), they do not
share the same breakpoints, and the actual copy number
also differs, with three and four copies respectively. Thus
although the alterations look fairly similar, they seem to
be the result of two different events. Finally, not only
does the daughter cell lines contain unique aberrations,
there are also a few alterations found to be specific for
SK-N-SH itself, for example an interstitial deletion at 4 q
which partly overlaps with another smaller interstitial
deletion, common to all three cell lines, thus causing a
homozygous deletion in the overlapping region.
All ten cell lines were also validated using STR geno-
typing, and the resulting profiles were compared against
public profiles at the Children’s Oncology Group data-
base. All our cell lines were found to match with the
previously reported profiles, and SK-N-SH, SH-EP and
SH-SY5Y were additionally found to have identical STR-
profiles thus confirming their shared ancestry (data
available on request).
Discussion
Frequency of CN-LOH in NB
CN-LOH has previously been reported in many types of
cancers [17] and to some extent in neuroblastoma [3].
However the amount of LOH that is truly copy neutral
found among primary NB tumors is rather low compared
to many other tumors [17]. In this paper we report a fre-
quency of near-CN-LOH in primary tumors (35%) that
differs from our previously reported frequency for NB
(3.3%) [3]. This difference is due to two important exten-
sions; first we have changed the definition of CN-LOH to
near-CN-LOH, thus accepting a wider range of abnorm-
alities in order to include the near-triploid tumors. Sec-
ond, we have extended the dataset by including 62
tumors not included in the first dataset.
The statistical analysis show that near-CN-LOH is
more common among NB-cell lines than primary NB
tumors (p = 0.002). This could implicate either that
CN-LOH is more common among relapsing tumors,
from which most cell lines are derived, or that CN-LOH
is an effect of cell line immortalization. Near-CN-LOH
was also found to be more frequent in the primary
tumors than in the healthy controls (p = 0.004),
although the healthy controls did present with near-CN-
LOH as well. Due to the lack of matched control sam-
ples in the material, we were unable to discriminate
between IBD and tumor derived CN-LOH in the
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between these groups indicates that at least some of the
near-CN-LOH in the tumors represents true tumor
acquired events.
Possible clinical implications
A sc a nb es e e ni nF i g u r e2 ,t h ep r i m a r yt u m o r ss o m e -
times display near-CN-LOH in regions of clinical and/or
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Figure 2 Near-CN-LOH in clinically interesting regions. Arrows indicate clinically interesting regions with near-CN-LOH (NB04, NB05 and
NB06) or gain-LOH (NB07). The CN-LOH in NB06 is shown in both genome-wide view and single chromosome view for comparison. Total copy
number is depicted as a multicolored or blue line in genome-wide view and single chromosome view respectively. The red and green lines
show the strongest and weakest allele intensity respectively for both views.
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not very common in NB, it still adds an extra complex-
ity to tumor genetics, and the total number of aberra-
tions in these regions might be higher than previously
thought. Thus by combining CN-LOH data with data
about deletions and gains, new regions of interest can
be identified and previously characterized regions can be
further defined. However, the possible clinical implica-
tions of CN-LOH are at the moment difficult to evalu-














Figure 3 Allelic imbalances in NB cell lines. Genome-wide chromatograms are shown for all the NB cell lines analyzed. Arrows indicate
regions of near-CN-LOH or Gain-LOH. The multicolored line shows the total copy number for the different chromosomes and the red and green
lines show the strongest and weakest allele intensity respectively.
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Figure 4 Clonal differences between cell lines. A) Genome-wide chromatograms for the highly related cell lines; SK-N-SH, SH-EP and SH-SY5Y.
Aberrations shared by all three cell lines are shown as black arrows, those that are shared by two of the cell lines are shown as grey arrows and
the ones unique to each cell line are shown as unfilled arrows. Note that all three cell lines have acquired new aberrations since the sub cloning
took place. The gains seen at 1 q for SH-SY5Y and SH-EP, although similar in this picture, are not identical in position and copy number and
probably represent two different events. Only aberrations larger than 1.5 Mb are indicated in the figure, with the exception of the homozygous
deletion at 9p21 in SH-EP. B) MLPA results confirming the deletion at 9p21 found in SH-EP, as well as the small gain found in SH-SY5Y in this
region. Neither of these aberrations can be seen in the parental cell line SK-N-SH. The whole chromosome gain at chromosome 7, seen in all
three cell lines, is also confirmed by the MLPA analysis.
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tional and imprinting status of the remaining allele.
Moreover, in contrast to a hemizygous deletion, CN-
LOH would not be expected to cause any haploinsuffi-
ciency effects, since the total copy number remains
normal.
Loss of heterozygosity in combination with gain of the
same region (Gain-LOH) is another very intriguing
aberration that was found in the material, e.g. in the 17
q region often affected with gain in aggressive NB
tumors (Figure 2). This abnormality is especially inter-
esting due to its dual nature, which makes simultaneous
promotion of both tumor suppressor genes and onco-
genes possible. For some oncogenic gain-of-function
mutations, such as the V617F mutation in the tyrosine
kinase JAK2 in myeloproliferative disorders, loss of the
wild type allele could actually give an advantage to the
tumor cell. This mutation targets the auto inhibitory
region of JAK2 and results in a constitutively active tyr-
osine kinase that confers growth factor independency as
well as cytokine hypersensitivity. The region surround-
ing JAK2 (9 p) frequently contains CN-LOH or Gain-
LOH in these diseases [22-25]. It has also been shown
that adding wild type JAK2 to cells carrying the mutated
JAK2 allele restores the growth factor dependency, indi-
cating that in this case it is in fact favorable if not
necessary for tumor progression to lose the wild type
allele [23].
The subtypes of CN-LOH might represent different
mechanisms
The subtypes of CN-LOH were found to differ in their
relative frequency between the three sample groups.
This probably reflects different modes of acquisition,
more or less common in the different groups. The
whole chromosome CN-LOH events could be explained
by either anaphase lag, causing loss of one allele fol-
lowed by reduplication, or nondisjunction causing two
sister chromatids to end up in the same cell. This could
occur either at mitosis as a tumor acquired event or at
meiosis as a germ line event [17,26]. Smaller segmental
CN-LOH (interstitial and telomeric), on the other hand,
probably arise in the tumors either through mitotic
recombination between low copy repeats or due to a
double-stranded-break repair error followed by redupli-
cation [17].
It is also possible that some of the CN-LOH seen in
the tumors might in fact represent IBD and not true
tumor acquired events. This mechanism can in theory
give rise to any of the different subgroups of CN-LOH.
However due to meiotic recombination, the CN-LOH
regions would be expected to become smaller with each
generation, thus making small, interstitial events more
likely than the larger telomeric or whole chromosome
events. This could explain at least part of the differences
in subtypes seen between the tumors and healthy con-
trols. It is also important to note that although tumor
derived CN-LOH is the primary interest here, IBD
events might be important for tumor development and
act as a first predisposing event towards cancer.
Genetic differences between cell lines
The array profiles, as well as the STR-genotyping, of the
three related cell lines SK-N-SH, SH-EP and SH-SY5Y
clearly confirmed that these cell lines are highly related
to each other, but some distinct features separating
these cell lines from each other was also found (Figure
4). It could be argued that these alterations were all pre-
sent in a mosaic manner in the parental cell line and
perhaps also in the original tumor, and that subcloning
later has resulted in more purified cell lines. An alterna-
tive hypothesis would be that aberrations found to differ
between the cell lines are in fact cell line derived events,
and thus a product of cell line evolution. The finding of
a gain at 2p16-pter, common to SK-N-SH and SH-SY5Y
but not SH-EP give some support to the former theory.
However, since each of the three cell lines also contain
unique aberrations that differ from the others, it seems
unlikely that this theory would account for all of the dif-
ferences seen. Even though the SK-N-SH line might
have lost some of its mosaicism over time, thus becom-
ing a more homogeneous cell line, the fact that extra
a b e r r a t i o n ss u c ha st h ed e l e tion of 4q26-28.3 is visible
only in SK-N-SH, still indicates that at least some of the
aberrations are acquired secondary to the subcloning.
T h ed a t aa l s os h o wt h a tb o t hS H - S Y 5 Ya n dS H - E P
contain an extra copy of 1 q, although with different
breakpoints and different copy number, thus presumably
acquired as two separate events. The parental cell line
SK-N-SH however, shows no sign of this aberration in
the material, which indicates that this is a later event.
According to early karyotypic data for these cell lines
[21], SHEP was found to contain an isochromosome 1 q
in 35% of the cells, resulting in 4 copies of the 1 q
region, while SH-SY5Y presented with a complex dupli-
cation of a large 1 q segment, resulting in 3 copies of
this region. SK-N-SH however was found to be karyoty-
pically normal for chromosome 1. This corresponds well
with the data presented here and explains the observed
difference in copy number seen between the cell lines.
However, other karyotypic information for these cell
lines has also been found in the literature [27-29],
resulting in a somewhat complex picture. Although
some of these differences can be explained by limita-
tions of the different methods used, for example the
lack of resolution in CGH and M-FISH studies or the
inability to find balanced translocations using SNP-
arrays, there are still some discrepancies between the
Kryh et al. BMC Genomics 2011, 12:443
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lines are used at different laboratories. The fact remains
that even relatively stable cell lines change over time
and that cell lines keep evolving, thus giving rise to
aberrations specific not to the original tumor but rather
to the cell culture environment itself. It is important to
be aware of the effects that might result from culturing
the cells for an extensive amount of passages and to
check the cell lines for genetic changes on a regular
basis.
Another interesting finding is that karyotypic informa-
tion in itself sometimes can be misleading. The cell line
SK-N-DZ used in this study was recently bought from
European Collection of Cell Cultures (ECACC, HPA
Culture Collections), where its karyotype is presented as
lacking both copies of chromosome 2. However, when
this cell line was analyzed with SNP-array it was found
that not only does chromosome two exist but a high
grade amplification of the MYCN gene was also present.
The copy number plot for chromosome 2 (except the
MYCN region) was mainly in the diploid range although
somewhat fragmented, indicating that the chromosome
might be broken into smaller pieces that are translo-
cated to other regions of the genome and thus hard to
detect using karyotyping. In fact the American Type
Culture Collection (ATCC) describes the karyotype of
this cell line as carrying 5 marker chromosomes of
unknown origin, which supports this finding. This high-
lights that high density SNP-arrays can give information
that is complementary to classical karyotype data, and
that it is important to compare data from different
sources in order to derive full information.
Conclusions
We have shown that NB tumors harbor several interest-
ing allelic imbalances that would either go unnoticed or
be misinterpreted using traditional array CGH methods
or other genome-wide techniques. Although the clinical
effects of these abnormalities on NB tumor development
and progression remains unknown, the findings indicate
that the genetics underlying NB might be even more
complex than previously known and that SNP arrays are
important analysis tools, capable of providing large
amounts of information in a single experiment.
We have also shown that these near-CN-LOH events
are more frequent in NB cell lines than in NB tumors
and that the type of CN-LOH differs between the
groups. Furthermore, when analyzing a set of highly
related cell lines, several aberrations were found to be
unique for each of the subclones which indicate that the
cell lines have continued to evolve secondary to the sub-
cloning event. Taken together this highlights that cell
lines in many cases differ substantially from the primary
tumors they are expected to represent, and that caution
should be taken when drawing conclusions from cell
line-based studies.
Additional material
Additional file 1: Aberrations that differ between the related cell
lines. Table of copy number changes that differs between the related
cell lines; SK-N-SH, SH-SY5Y and SH-EP. Gain = 1-3 extra copies, Del =
loss of 1 copy (unless stated otherwise in the comments), pter and qter
refer to the p- and q-terminal of the chromosome respectively.
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